Cellular Therapy for Fanconi Anemia: The Past, Present, and Future

被引:16
|
作者
MacMillan, Margaret L. [1 ]
Hughes, Mark R. [2 ]
Agarwal, Suneet [3 ,4 ,5 ,6 ,7 ]
Daley, George Q. [3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Appl Genom Technol Ctr Michigan, Genesis Genet Inst, Detroit, MI USA
[3] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[7] Harvard Stem Cell Inst, Boston, MA USA
关键词
BONE-MARROW-TRANSPLANTATION; PLURIPOTENT STEM-CELLS; APLASTIC-ANEMIA; DONORS; CYCLOPHOSPHAMIDE; IRRADIATION; DISEASE; BLOOD; ENGRAFTMENT; GENERATION;
D O I
10.1016/j.bbmt.2010.11.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hematologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such that transplant outcomes have markedly improved. With the development of in vitro fertilization and preimplantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors. Biol Blood Marrow Transplant 17: S109-S114 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
引用
收藏
页码:S109 / S114
页数:6
相关论文
共 50 条